Latest News and Press Releases

Vertero doses first Parkinson’s patient in Phase 1b study of VT-5006, a gut-selective therapy targeting disease progression.

– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA –  – End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for...

CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...

– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in...

LeonaBio, Inc. (NASDAQ: LONA), announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter Silverman, J.D. to its Board of Directors.

MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...

Trethera to present optic neuritis research, highlighting TRE-515, a first-in-class oral inhibitor of dCK, advancing a novel autoimmune disease treatment.

MMI today announced completion of the first robotic-assisted procedure in REMIND, its U.S. Investigational Device Exemption (IDE) Study

Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSAAdvancing ATH434 toward pivotal Phase 3 program; on track for...

Freiburg, Germany, April 29, 2026 (GLOBE NEWSWIRE) -- CorTec GmbH today announced that the first participant in the University of Washington’s NIH-funded clinical trial of the Brain Interchange™...